Background Boceprevir has recently changed hepatitis C virus (HCV) treatment by greatly improving sustained virological response (SVR) rates.
Purpose To identify predictive factors of SVR in HCV-infected patients receiving triple therapy including boceprevir.
Materials and methods We conducted a retrospective observational study. Medical records of patients on boceprevir treatment between 01/2012–05/2013 in a tertiary hospital were reviewed. Patients were included if they were ≥18 years, had finished their HCV treatment and had a measurable viral load six months after the end of the HCV treatment. Demographic and laboratory data were collected at the start of the HCV treatment. Besides this, virological responses were compiled at weeks four, eight and twelve from the start of the treatment as well as at the end of treatment and the six months later. The chi-squared test and logistic regression were performed to examine the role of the different variables on the SVR, using SPSS 19.0.
Results 19 [45%] patients achieved SVR versus 23 [70%] who did not. No statistically-significant differences were observed for the variables sex [68% male vs. 70%]; fibrosis stage [6% F2 vs. 0%, 27% F3 vs. 17%, 67% F4 vs. 83%]; HIV-HCV coinfection [26% vs. 13%]; baseline haemoglobin [150 ± 16 mg/dl vs. 147 ± 16]; AST [61 ± 47 mU/ml vs. 70 ± 38] and ALT [78 ± 61 mU/ml vs. 72 ± 42] levels. In contrast, differences were founded in age [52 ± 7 years vs. 57 ± 9] and in viral load reduction after the lead-in [24% <1 log vs. 64%]. The Chi-squared test showed a statistically-significant relationship between SVR and undetectable viral load at weeks eight and twelve, as well as at the end of treatment. Logistic regression showed that viral load at week eight (OR: 5.03 [95% CI:1.25–20.19]) was the only independent predictor of SVR. This association remained significant after controlling independently for age.
Conclusions Undetectable viral load at week eight of treatment was identified as the strongest predictor of SVR in patients on boceprevir treatment.
No conflict of interest.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.